Harrow Health Inc (HROW)
Official siteHEALTHCARE • DRUG MANUFACTURERS - SPECIALTY & GENERIC • NASDAQ
Market Cap: $1.13B
Last updated: Nov 17, 2026 at 11:05 AM ET
Harrow Health Inc (HROW) Earnings: Report Dates and Results
Harrow Health (HROW) is confirmed to report earnings on Mar 1, 2027, after the close. In the quarter ended Sep 30, 2026, Harrow Health reported EPS of $0.12, below the $0.13 estimate. It beat the EPS estimate in 3 of the 8 most recent quarters that had an estimate.
Earnings
Performance (10Y)
Upcoming Estimates
Next Report
HROW has a confirmed report date of Mar 1, 2027, after the close. Analysts' consensus for the quarter ending Dec 31, 2026 is 114.8% above the $0.27 reported for the quarter ended Dec 31, 2025.
HROW Earnings Call
The latest HROW earnings call transcript on file is labeled 2026Q3.
Read the 2026Q3 transcriptEarnings History
Of the 36 quarters below that had an estimate, HROW beat 18, missed 16 and matched 2. Revenue for the quarter ended Sep 30, 2026 was $99.30M, up 38.6% from $71.64M a year earlier.
| Quarter ended | EPS | Estimate | Range | Surprise | Result | YoY | Analysts | Revisions | Reported | Revenue |
|---|---|---|---|---|---|---|---|---|---|---|
| Sep 30, 2026 | $0.12 | $0.13 | $0.12 - $0.48 | -7.69% | Miss | -63.6% | 4 | 0 up, 3 down | Nov 9, 2026 | $99.30M |
| Jun 30, 2026 | -$0.34 | -$0.23 | -$0.50 - -$0.02 | -47.83% | Miss | -241.7% | 3 | 0 up, 1 down | Aug 10, 2026 | $70.66M |
| Mar 31, 2026 | -$0.74 | -$0.33 | -$0.33 - -$0.33 | -124.24% | Miss | N/A | 1 | 0 up, 1 down | May 11, 2026 | $44.20M |
| Dec 31, 2025 | $0.27 | $0.39 | N/A | -31.07% | Miss | -33.1% | 2 | 1 up, 2 down | Mar 2, 2026 | $89.09M |
| Sep 30, 2025 | $0.33 | $0.29 | $0.18 - $0.36 | +13.79% | Beat | N/A | 3 | 1 up, 0 down | Nov 10, 2025 | $71.64M |
| Jun 30, 2025 | $0.24 | $0.04 | N/A | +500.00% | Beat | N/A | 4 | 0 up, 0 down | Aug 11, 2025 | $63.74M |
| Mar 31, 2025 | -$0.38 | $0.01 | -$0.01 - $0.02 | N/A | N/A | N/A | 3 | 0 up, 2 down | May 8, 2025 | $47.83M |
| Dec 31, 2024 | $0.40 | $0.13 | $0.06 - $0.24 | +207.69% | Beat | N/A | 3 | 1 up, 0 down | Mar 27, 2025 | $66.83M |
| Sep 30, 2024 | -$0.05 | $0.07 | N/A | -171.43% | Miss | N/A | 4 | 0 up, 0 down | Nov 13, 2024 | $49.26M |
| Jun 30, 2024 | -$0.06 | -$0.11 | N/A | +45.45% | Beat | N/A | 4 | 0 up, 0 down | Aug 7, 2024 | $48.94M |
| Mar 31, 2024 | -$0.28 | -$0.25 | -$0.27 - -$0.06 | -12.00% | Miss | N/A | 4 | 0 up, 0 down | May 13, 2024 | $34.59M |
| Dec 31, 2023 | -$0.25 | -$0.04 | -$0.08 - -$0.02 | -525.00% | Miss | -725.0% | 3 | 0 up, 0 down | Mar 19, 2024 | $36.35M |
| Sep 30, 2023 | -$0.09 | $0.03 | -$0.05 - $0.15 | -400.00% | Miss | N/A | 3 | 0 up, 0 down | Nov 13, 2023 | $34.27M |
| Jun 30, 2023 | -$0.02 | -$0.04 | -$0.12 - $0.03 | +50.00% | Beat | -300.0% | 3 | 1 up, 0 down | Aug 9, 2023 | $33.47M |
| Mar 31, 2023 | -$0.03 | -$0.06 | -$0.10 - -$0.03 | +50.00% | Beat | -200.0% | 3 | 0 up, 1 down | May 11, 2023 | $26.10M |
| Dec 31, 2022 | $0.04 | -$0.12 | -$0.15 - -$0.05 | +133.33% | Beat | N/A | 3 | 0 up, 0 down | Mar 23, 2023 | $20.33M |
| Sep 30, 2022 | -$0.20 | -$0.03 | -$0.04 - $0.04 | -566.67% | Miss | -600.0% | 4 | 0 up, 0 down | Nov 14, 2022 | $22.82M |
| Jun 30, 2022 | $0.01 | $0.01 | N/A | 0.00% | In line | -88.9% | N/A | 0 up, 0 down | Aug 9, 2022 | $23.32M |
| Mar 31, 2022 | $0.03 | -$0.04 | -$0.05 - $0.00 | +175.00% | Beat | -66.7% | 4 | 0 up, 0 down | May 5, 2022 | $22.12M |
| Dec 31, 2021 | -$0.27 | -$0.04 | -$0.10 - $0.08 | -575.00% | Miss | -775.0% | 4 | N/A | Mar 10, 2022 | $20.19M |
| Sep 30, 2021 | $0.04 | -$0.03 | -$0.17 - $0.07 | +233.33% | Beat | 0.0% | 4 | N/A | Nov 9, 2021 | $18.71M |
| Jun 30, 2021 | $0.09 | $0.04 | N/A | +125.00% | Beat | N/A | 2 | N/A | Aug 10, 2021 | $18.13M |
| Mar 31, 2021 | $0.09 | $0.02 | N/A | +350.00% | Beat | N/A | 2 | N/A | May 11, 2021 | $15.44M |
| Dec 31, 2020 | $0.04 | $0.04 | -$0.01 - $0.05 | 0.00% | In line | -60.0% | 2 | N/A | Mar 8, 2021 | $40.81M |
| Sep 30, 2020 | $0.04 | -$0.09 | -$0.10 - $0.17 | +144.44% | Beat | N/A | 2 | N/A | Nov 9, 2020 | N/A |
| Jun 30, 2020 | -$0.14 | -$0.17 | N/A | +17.65% | Beat | N/A | 2 | N/A | Aug 10, 2020 | $8.06M |
| Mar 31, 2020 | -$0.04 | -$0.02 | -$0.50 - -$0.01 | -100.00% | Miss | N/A | 2 | N/A | May 11, 2020 | N/A |
| Dec 31, 2019 | $0.10 | $0.06 | -$0.02 - $0.13 | +66.67% | Beat | -87.0% | 2 | N/A | Mar 13, 2020 | $12.60M |
| Sep 30, 2019 | -$0.29 | -$0.04 | N/A | -625.00% | Miss | N/A | 2 | N/A | Nov 13, 2019 | $12.76M |
| Jun 30, 2019 | -$0.05 | -$0.06 | N/A | +16.67% | Beat | -145.5% | 2 | N/A | Aug 14, 2019 | $13.52M |
| Mar 31, 2019 | -$0.04 | -$0.12 | -$0.15 - $0.12 | +66.67% | Beat | N/A | 2 | N/A | May 9, 2019 | $12.29M |
| Dec 31, 2018 | $0.77 | $0.34 | N/A | +126.47% | Beat | N/A | N/A | N/A | Mar 12, 2019 | $22.12M |
| Sep 30, 2018 | -$0.12 | -$0.09 | N/A | -33.33% | Miss | N/A | N/A | N/A | Nov 13, 2018 | N/A |
| Jun 30, 2018 | $0.11 | -$0.12 | N/A | +191.67% | Beat | N/A | N/A | N/A | Aug 6, 2018 | $10.38M |
| Mar 31, 2018 | -$0.17 | -$0.16 | N/A | -6.25% | Miss | N/A | N/A | N/A | May 15, 2018 | $8.87M |
| Dec 31, 2017 | -$0.13 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | Mar 8, 2018 | $7.34M |
| Sep 30, 2017 | -$0.28 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | Nov 14, 2017 | $6.48M |
| Jun 30, 2017 | -$0.26 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | Aug 10, 2017 | $6.86M |
| Mar 31, 2017 | -$0.21 | -$0.19 | N/A | -10.53% | Miss | N/A | N/A | N/A | May 10, 2017 | $6.10M |
| Dec 31, 2016 | -$0.30 | -$0.28 | N/A | -7.14% | Miss | N/A | N/A | N/A | Mar 21, 2017 | $5.79M |
Annual EPS
EPS for the fiscal year ended Dec 31, 2025 was $0.46, up 4475.0% from the year before. It was -$1.26 for the year ended Dec 31, 2016, the oldest of the 10 fiscal years shown.
| Fiscal year ended | EPS | Change |
|---|---|---|
| Dec 31, 2025 | $0.46 | +4475.0% |
| Dec 31, 2024 | $0.01 | N/A |
| Dec 31, 2023 | -$0.39 | N/A |
| Dec 31, 2022 | -$0.12 | N/A |
| Dec 31, 2021 | -$0.05 | N/A |
| Dec 31, 2020 | -$0.10 | N/A |
| Dec 31, 2019 | -$0.28 | -147.5% |
| Dec 31, 2018 | $0.59 | N/A |
| Dec 31, 2017 | -$0.88 | N/A |
| Dec 31, 2016 | -$1.26 | N/A |
Earnings Calls
The 8 most recent earnings calls are listed below; the latest, 2026Q3 for the period ended Sep 30, 2026, runs about 8,600 words across 14 speakers.
| Call | Period ending | Words | Speakers | Transcript |
|---|---|---|---|---|
| 2026Q3 | Sep 30, 2026 | 8,624 | 14 | |
| 2026Q2 | Jun 30, 2026 | 8,869 | 13 | |
| 2026Q1 | Mar 31, 2026 | 7,044 | 13 | |
| 2025Q4 | Dec 31, 2025 | 10,881 | 13 | |
| 2025Q3 | Sep 30, 2025 | 9,095 | 13 | |
| 2025Q2 | Jun 30, 2025 | 6,826 | 11 | |
| 2025Q1 | Mar 31, 2025 | 6,094 | 9 | |
| 2024Q3 | Sep 30, 2024 | 5,225 | 8 |
2026Q3 Earnings Call
Opening remarks
Michael Biega Vice President of Investor Relations and Communications Thank you, operator. Good morning, and welcome to Harrow's Third Quarter 2026 Earnings Conference Call. My name is Mike Biega, Vice President of Investor Relations and Communications. The company's remarks may include forward-looking statements within the meaning of federal securities laws. Forward-looking statements are subject to numerous risks and uncertainties, many of which are beyond Harrow's control, including risks and uncertainties described from time to time in its SEC filings, such as the risks and uncertainties related to the company's ability to make commercially available its FDA-approved products and compounded formulations and technologies, and FDA approval of certain drug candidates in a timely manner or at all. For a list and description of those risks and uncertainties, please see the Risk Factors section of the company's most recent annual report on Form 10-K and subsequent quarterly reports on Form 10-Q filed with the Securities and Exchange Commission. Harrow's results may differ materially from those projected. Harrow disclaims any intention or obligation to update or revise any financial projections or forward-looking statements, whether because of new information, future events, or otherwise. This conference call contains time-sensitive information and is accurate only as of today. Additionally, Harrow will refer to non-GAAP financial metrics, specifically adjusted EBITDA. A reconciliation of any non-GAAP measures with the most directly comparable GAAP measure is included in the company's earnings release and letter to stockholders, both of which are available on the website. Joining me on today's call are Mark L. Baum, Founder, Chairman and Chief Executive Officer; Andrew Boll, President and Chief Financial Officer; Patrick Sullivan, Chief Commercial Officer; and Amir Shojaei, Chief Scientific Officer. With that, I would like to turn the call over to Mark. Mark?
Mark Baum Founder, Chairman and CEO Thanks, Mike, and good morning, everyone. Last quarter, I was clear. Our priority was turning the demand we were building into revenue. In the third quarter, that's exactly what happened, and it's the clearest sign yet that the second half is playing out as we expected. Demand is growing across key products. Our expanded commercial team is getting more productive every month, and we're reaffirming our full-year revenue guidance. We're continuing our momentum, and I expect the fourth quarter to be the strongest quarter in Harrow's history. I also believe you will see our momentum continue into 2027. You see it in VEVYE, which delivered record revenue as our expanded sales force matures and begins to deliver improved prescription economics. You see it in TRIESENCE, which had its strongest quarter under Harrow ownership. And you see it in IHEEZO, which heads into its historically strongest quarter with new clinical evidence from QUELL.
Frequently Asked Questions About HROW
When is Harrow Health's next earnings date?
Harrow Health's next earnings report is confirmed for Mar 1, 2027, after the close.
Did HROW beat earnings estimates last quarter?
No. Harrow Health reported EPS of $0.12 for the quarter ended Sep 30, 2026, below the $0.13 estimate by 7.69%.
What EPS do analysts expect from HROW next quarter?
The consensus EPS estimate for Harrow Health for the quarter ending Dec 31, 2026 is $0.58 from 11 analysts, with estimates from $0.33 to $0.79.
How often does HROW beat earnings estimates?
Harrow Health beat the EPS estimate in 3 of the 8 most recent quarters that had an estimate, with an average surprise of +42.40%.
Does HROW report before or after the market opens?
Harrow Health is confirmed to report on Mar 1, 2027, after the market closes.
HROW pages: Overview, Earnings, Forecast, Financials, Valuation, Competitors